Literature DB >> 1735466

Biochemical and behavioral recovery in a rodent model of Parkinson's disease following stereotactic implantation of dopamine-containing liposomes.

M J During1, A Freese, A Y Deutch, P G Kibat, B A Sabel, R Langer, R H Roth.   

Abstract

We have developed and characterized dopamine-containing liposomes which exhibited in vitro sustained release of dopamine for over 40 days. These liposomes were stereotactically implanted into the partially denervated corpus striatum of rats subjected to unilateral lesions of the substantia nigra. In vivo release of dopamine into striatal extracellular fluid was monitored by microdialysis and behavior was assessed by quantifying apomorphine-induced asymmetric rotation. Extracellular dopamine levels in the partially denervated striatum of the dopamine liposome-treated rats were greater than the levels in the lesioned rats which received control liposomes and these levels remained elevated for 25 days. In parallel, those rats which received dopamine liposomes exhibited partial behavioral recovery, with attenuation of asymmetric rotation following systemic apomorphine administration. These results suggest that dopamine-containing liposomes can partially ameliorate the deficits associated with a rodent model of Parkinson's disease, and demonstrate the potential of this technology as a method for the controlled delivery of therapeutic agents into discrete areas of the brain.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1735466     DOI: 10.1016/0014-4886(92)90053-s

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  9 in total

Review 1.  Nanotechnology-based drug delivery systems for targeting, imaging and diagnosis of neurodegenerative diseases.

Authors:  Sibel Bozdağ Pehlivan
Journal:  Pharm Res       Date:  2013-10       Impact factor: 4.200

Review 2.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

Review 3.  GABA-containing liposomes: neuroscience applications and translational perspectives for targeting neurological diseases.

Authors:  Marco Antônio Peliky Fontes; Gisele Cristiane Vaz; Thais Zielke Dias Cardoso; Mariana Flávia de Oliveira; Maria José Campagnole-Santos; Robson Augusto Souza Dos Santos; Neeru M Sharma; Kaushik P Patel; Frédéric Frézard
Journal:  Nanomedicine       Date:  2017-12-24       Impact factor: 5.307

4.  Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson's disease.

Authors:  Mei Sun; Lingxin Kong; Xiaodan Wang; Xiu-gui Lu; Qingsheng Gao; Alfred I Geller
Journal:  Brain Res       Date:  2005-08-09       Impact factor: 3.252

5.  Nanoparticles for drug delivery in Parkinson's disease.

Authors:  Jonathan Baskin; June Evelyn Jeon; Simon J G Lewis
Journal:  J Neurol       Date:  2020-11-03       Impact factor: 4.849

6.  Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).

Authors:  Carlos Spuch; Carmen Navarro
Journal:  J Drug Deliv       Date:  2011-12-13

Review 7.  Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.

Authors:  Mine Silindir Gunay; A Yekta Ozer; Sylvie Chalon
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

Review 8.  Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier.

Authors:  Débora B Vieira; Lionel F Gamarra
Journal:  Int J Nanomedicine       Date:  2016-10-18

Review 9.  Rafts, Nanoparticles and Neural Disease.

Authors:  Vishal Gulati; Ron Wallace
Journal:  Nanomaterials (Basel)       Date:  2012-08-06       Impact factor: 5.076

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.